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Abstract: Forward genetics in humans is beneﬁcial in terms of diagnosis and treatment of
genetic diseases, and discovery of gene functions. However, experimental mating is not possible
among humans. In order to overcome this problem, I propose a novel experimental procedure to
genetically identify human disease gene loci. To accomplish this, somatic cells from patients or
their parents are reprogrammed to the pluripotent state, oogenesis is induced, the oocytes are
parthenogenetically activated in the presence of cytochalasin, and embryonic stem cells are
established from the parthenogenetic blastocysts. This protocol produces a set of diploid pluripotent
stem cell clones having maternal and paternal chromosomes in diﬀerent manners to each other. The
genetic loci for the disease genes are determined through the conventional processes of positional
cloning. Thus, taking advantage of the strategy proposed here, if the abnormality is reproducible
using patient-derived pluripotent stem cells, a single carrier of the genetic mutations would be
adequate to identify the disease gene loci.
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Introduction
There are many types of human genetic diseases.
Identiﬁcation of the mutations responsible for these
diseases is beneﬁcial in terms of diagnosis and
treatment of genetic diseases, and discovery of gene
functions. However, experimental mating to identify
the responsible gene loci is not possible in humans.
In addition, the generation time of humans is so long
that only a few persons received a certain genetic
mutation. These restrictions make it diﬃcult to
identify disease genes in humans.
Therefore, in human genetic studies, data on
symptoms and genotypes need to be collected from
a number of patients and controls. This takes much
cost to identify the disease genes. In addition,
mutations in various genes cause similar symptoms
if the aﬀected genes contribute to the same functions
(locus heterogeneity). Thus, the method for conven-
tional human genetics that may together analyze
many patients who carry diﬀerent mutations in
diﬀerent genes makes the problems diﬃcult.
Recently, the whole-genome sequence of patients
in a family was determined to identify the candidate
genes of Mendelian disorders using “next generation
sequencing” technology.1),2) Because there are mil-
lions of genetic polymorphisms in each human
genome, one have to hypothesize (e.g., homozygous
mutations, nonsynonymous mutations, mutations
in functional gene units, genes known to function in
the abnormal tissues of diseases, and so on) to pick
out the responsible mutations of the diseases.1),2)
In addition, each person has diﬀerent sensitivities
to certain disease genes because of the diversity of
the genetic background in humans. In fact, there
are many mutations, including both heterozygous
dominant mutations and homozygous recessive
mutations, responsible for certain diseases in the
genomes of people not aﬀected by the diseases.1)
Thus, it may be diﬃcult to accurately identify
the disease-responsible mutations out of the known
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of heterozygous polygenic disorders using whole-
genome sequencing technology if only a few patients
are available.
Because of these technical limitations in human
genetics, the genes responsible for many diseases have
still not been identiﬁed. In particular, it is diﬃcult
to identify susceptible genes for polygenic diseases.
In the case of idiopathic generalized epilepsy (IGE),
combinations of several susceptibility genes are
thought to be risk factors for the disease.4) Each of
the susceptibility genes is supposed to have a small
eﬀect and be neither necessary nor suﬃcient to cause
epilepsy.5) This results in high heterogeneity of the
susceptible gene loci in patients with IGE.6) Thus,
despite hundreds of genetic association studies on
epilepsy, the mutations responsible for IGE have not
been deﬁnitively identiﬁed.7)
In order to overcome the abovementioned
diﬃculties, I propose a novel experimental procedure
to genetically identify the gene loci responsible for
human genetic disorders. Taking advantage of the
strategy proposed here, if the abnormality of the
disease is reproducible using patient-derived pluri-
potent stem cells, a single carrier of the genetic
mutations would be enough to identify the disease
gene loci.
Method
The gene loci responsible for human genetic
disorders are experimentally determined in the order
described below (Figs. 1, 2). This method is appli-
cable to many types of inheritance, such as dominant,
recessive, and multigenic traits.
(1) Induction of pluripotent stem cells.
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Fig. 1. Identiﬁcation of disease gene loci without experimental mating, an example of a Mendelian disorder in an autosomal dominant
trait. (A) Reproduction of genetic disorders. iPS cells are established from somatic cells of patients and unaﬀected controls (left of
arrows). The iPS cells are induced to diﬀerentiate into an appropriate type of cell in vitro or in vivo (arrow). Functions of the
diﬀerentiated cells are analyzed to detect abnormalities (right of arrows). (B) iPS cells carrying heterozygous mutations are subjected
to oogenesis. Meiotic recombination occurs at pachytene stage. In the case of oogenesis, meiosis arrests at the end of the ﬁrst meiotic
prophase and the second meiotic metaphase. (C) Oocytes are parthenogenetically activated, and the genetic loci for diseases are
identiﬁed genetically. The oocytes at the ﬁrst meiotic prophase or second meiotic metaphase are stimulated to induce parthenogenesis.
Diploid pluripotent stem cells are obtained from the parthenogenetic oocytes pretreated with cytochalasin. Each ES cell clone from
the parthenogenetic embryo has maternal and paternal chromosomes in diﬀerent ratios (left of arrows). Each ES cell clone is analyzed
as described in (A) (right of arrows). Genotypes and phenotypes of the clones are analyzed to identify the genetic loci of the mutations
responsible for the diseases using the conventional procedure for positional cloning.
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cells8)–11) (Figs. 1A and 2A). Reprogramming factors
should be introduced into the cells so as to not alter
the genomic sequences. Plasmid vector,12),13) trans-
posons,14),15) and recombinant proteins16),17) can be
used to introduce these factors into the cells. Chemi-
cal reagents are also useful to increase the eﬃciency
of reprogramming.18),19)
(2) Detection of abnormalities. Assay
systems are established to distinguish the aﬀected
iPS cells from the normal control (Fig. 1A).
Nonketotic hyperglycinemia (NKH) is a genetic
disorder aﬀecting glycine metabolism.20) In the NKH
patients examined in a previous study, glycine
cleavage activity in liver homogenates was severely
defective.21) In most cases, NKH is caused by an
abnormality in one of three components of the
glycine cleavage multi-enzyme system (GLDC,
AMT,a n dGCSH).20) However, the disease-respon-
sible genes have not yet been identiﬁed in a few
exceptional patients with NKH.22) In NKH, the
aﬀected iPS cells might be distinguished from the
normal controls after diﬀerentiation into hepatocytes
and quantiﬁcation of their glycine metabolic activ-
ities.
As another example, in the case of IGE,
expression levels of GLT1, a glial glutamate trans-
porter, decrease23) and Iba1, an actin-crosslinking
molecule in microglia, increases24) in the brains of EL
mice, an animal model of IGE. Even in the case of a
systemic disease such as IGE, the patient’s iPS cells
may also be distinguished from the normal controls,
if the expression level of the human counterpart of
GTL1 or Iba1 is abnormal in glial cells diﬀerentiated
from patient-derived iPS cells.
(3) Induction of meiosis. Meiosis is induced in
patient-derived iPS cells (Figs. 1B and 2B). A hetero-
zygote of responsible mutations is used. In the case
of genetic disorders in an autosomal recessive trait,
cells from the parents of the patients are analyzed.
Oogenesis is chosen for the meiosis of iPS cells because
of its compatibility with the following procedures.
Creating functional germ line cells from iPS cells
is a signiﬁcant problem. However, when chimeric
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Fig. 2. Schematic representation of a possible experimental procedure to genetically identify human disease genes. Technical possibility
of the proposal must be examined. In case that more suitable method becomes available (ex. functional oogeneis from iPS cells
in vitro), it should replace the corresponding step as far as it satisﬁes the concept of Fig. 1. (A) Somatic cells from a patient or carrier
of the genetic mutations are reprogrammed to iPS cells. The iPS cells are diﬀerentiated into PGCs in the presence of BMPs.
(B) Primitive-streak-stage embryos are obtained from pregnant mice at 7.25–7.5dpc. PGCs puriﬁed in (B) are injected into a place,
where endogenous PGCs gather at this stage. The chimeric embryos are cultured until the embryos develop into the stage equivalent
to E10.5, when the PGCs reach the urogenital ridges. The urogenital ridges containing iPS cell-derived PGCs are collected and
cultured to develop into an ovary-like structure. The cultured organs are transplanted into adult female animals to allow the oocytes
to mature. (C) Oocytes from the transplanted ovaries are activated to induce parthenogenesis in the presense of cytochalasin. ES cells
derived from the parthenogenetic blastocysts (pES cell) are diﬀerentiated into a particular type of cell for cellular function analyses.
Genomic DNA is extracted from the cells to determine their genotypes. Genetic analyses between the phenotypes and genotypes of the
cells are performed.
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iPS cell-derived germ cells are known to be formed in
the body. The following describes my thoughts on the
ethically unproblematic application of that method
to human iPS cells.
Human ES cells are characteristically similar to
mouse epiblast stem cells, which are epiblast-derived
pluripotent stem cells, rather than to ES cells derived
from mouse blastocyst inner cell mass.25),26) Human
ES cells tend to be more prone to become primordial
germ cells (PGCs) in response to bone morphogenetic
proteins (BMPs)27) than mouse ES/iPS cells in vitro.
In the case of mouse system, when a tissue fragment
containing PGCs is transplanted into a space at
the junction of the allantois with the root of the
amnion of a primitive streak-stage mouse embryo,
the exogenous PGCs can start to migrate toward
the genital ridge in the same way as the endogenous
PGCs as the embryo develops.28) E7.5 mouse
embryos (containing primitive streak-stage mouse
embryo) can be developed into E10.5 equivalent
embryos by 3 days of whole embryo culture.29),30) In
addition, an E10.5 embryo urogenital ridge region
can be organ cultured and diﬀerentiated into an
ovarian-like tissue, but not a testis.31),32) Further,
ovaries derived from E12.5 (the time point when
ovary structures appear in female embryos) or later
mouse fetuses can be transplanted into ovariectom-
ized female mice and matured in the mouse’s
body.33)–36) In addition, male PGCs, as well as female
PGCs, can develop as oocytes in female embryos.37)
Using these techniques together, oocytes may
be generated from patient-derived iPS cells in the
fetus-derived ovaries as depicted in Fig. 2; however,
this will need to be conﬁrmed experimentally in the
future.
The production of gametes from pluripotent
stem cells in vitro has been studied extensively. Thus,
meiotic induction, including normal homologous
recombination of chromosomes, may be applied to
iPS cells in vitro in future.
In the ovaries of mice, oogonia enter the meiotic
phase on embryonic day 13.5, and the immature
oocytes are arrested after the diplotene of the ﬁrst
meiotic prophase.38) In immature oocytes at the
diplotene stage, the number of the chromosomes
is 4n, and recombination between the homologous
chromosomes is complete.39) The meiotic process of
the oocytes proceeds again shortly before ovulation
and stops at the second meiotic metaphase. At this
point, the number of chromosomes in the oocytes
is 2n, and each pair of homologous chromosomes
consists of those of maternal and paternal origin in
various ratios (Fig. 1B). Therefore, some oocytes
have homozygous genetic mutations, while others
have heterozygous or no mutations (Fig. 1C).
(4) Parthenogenesis of oocytes. Oocytes
that are arrested at the ﬁrst meiotic prophase or
second meiotic metaphase are collected and culti-
vated in vitro. Next, these are stimulated to induce
parthenogenesis (Fig. 2C). If the oocytes are treated
with cytochalasin when parthenogenetically acti-
vated to prevent extrusion of the polar bodies during
meiosis, the parthenogenetic embryos keep diploidy
and possess maternal and paternal chromosomes
in various ratios40),41) (Figs. 1C, 3A). Parthenoge-
netic embryonic stem (pES) cell clones are collected
from the resultant blastocysts of the parthenogenetic
embryos42),43) and cultured separately in wells of
culture plates (Fig. 2C).
Parthenogenetic embryos of wild-type mice
cannot complete ontogeny. However, pES cells of
mice diﬀerentiate into many types of cells if injected
into normal embryos or cultured in vitro.44),45) In the
case of humans, parthenogenetic cells are also known
to diﬀerentiate into many types of cells as ovarian
teratomas.
(5) Phenotyping of the clones. The pES
cell clones in each well are induced to diﬀerentiate
into appropriate cells, and the cellular functions are
examined (Figs. 1C and 2C) using the assay systems
established in the previous step (Fig. 1A). The clones
carrying the mutations responsible for the diseases
show abnormality in their functions, while those
without the mutations have normal phenotypes
(Fig. 1C).
(6) Genetic analysis. Genomic DNA is
obtained from each clone (Fig. 2C). The responsible
or susceptible gene loci for the diseases are identiﬁed
by standard procedures of genetic analysis, integrat-
ing the information of the phenotype and genotype
of each clone (Fig. 2C). The availability of parthe-
nogenetic embryos for the genetic mapping of certain
genes in mice and humans has been discussed
previously.43),46)–48)
Hotspots for meiotic homologous recombina-
tion exist in every 10–100kb on human chromo-
somes.49),50) Therefore, the resolution of this method
to identify the genetic loci may be 10–100kb.
Mutations responsible for the diseases are
identiﬁed by comparing the nucleotide sequences of
the responsible loci of the patients and controls.
Although the number of samples necessary to
determine disease gene loci depends on the complex-
T. MUTO [Vol. 87, 94ity of the disease, given that hundred samples from
persons are necessary to identify the loci of a certain
disease within a 1cM-region, hundred oocytes would
give a similar result using experimental procedure
proposed. To save the cost of genotyping, a following
strategy is available. A part of the hundred clones is
subjected to ﬁrst genome-wide analysis to roughly
narrow down the loci in a 20cM-region, for example,
and only the clones having recombination points
within it (approximately 20 clones out of a hundred)
are secondly analyzed intensively for ﬁne mapping of
the loci.
(7) Functional analysis. To conﬁrm the
responsible mutations experimentally, iPS cells from
patients are genetically modiﬁed and rescued from
the symptoms. Transfection of the wild-type genes,
knockdown of the disease genes using RNA interfer-
ence, and introduction of mutations into genomic
DNA51),52) can be used to rescue the patient-derived
iPS cells. The assay system mentioned in (2) is
available to examine abnormalities of the cells.
Discussion
Bioethical practicability. The experimental
method currently proposed will (i) contribute to the
development of new diagnostic methods, and (ii)
require highly eﬃcient homologous recombination of
chromosomes during meiosis. Therefore, creation of
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Fig. 3. Variable inheritance of chromosomes and mutations in experimental human genetics. (A) Chromosomal segregation during
parthenogenesis. Chromosomal segregation during meiosis and parthenogenesis is depicted. Bars and thick circles represent arms and
centromeres of the chromosomes, respectively. Chromosomes originating from diﬀerent parents are drawn in diﬀerent colors (black
and red). Chromosomes are inherited by p(MI) and p(MII) clones in diﬀerent manners. (B, C) Various combinations of mutations and
the onset of diseases. Schematic representation of various cases in polygenic diseases (B) and the cases in which mutations and
genomic imprinting are located in same loci (C). Black bars and X in circles represent chromosomes and mutations, respectively. Red
X, dominant mutation; blue X, recessive mutation; Red circle, aﬀected patients or clones. Red triangles represent mutations that lead
to 50% inactivation of the genetic loci, and black squares represent genetic loci inactivated by genomic imprinting. For explanation of
each case, refer to text.
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of this technique is ethically permissible. (Article 4 of
the “Policy on Research Involving the Creation of
Germ Cells from Human iPS Cells or Human Tissue
Stem Cells,” brought into eﬀect on May 20, 2010 by
the Ministry of Education, Culture, Sports, Science
and Technology. In this policy, PGCs are deﬁned as
germ cells.)
In addition, as the human parthenogenetic
embryos created by this study are not human embryos
as deﬁned in the Act on Regulation of Human Cloning
Techniques (Act No. 146, December 6, 2000) (A cell or
a cell group that has the potential to grow into an
individual through the process of development in utero
of a human or an Animal), their creation is possible.
Also, while injecting PGC into an animal
embryo corresponds to the creation of an “Animal-
Human Chimeric Embryo” as deﬁned in the Act on
Regulation of Human Cloning Techniques (in this
Act, PGCs are deﬁned as somatic cells), the Act does
not place any restrictions on the handling of animal-
human chimeric embryos. (Even human-animal
chimeric embryos do not infringe the Act provided
they are not transplanted into a human or animal
uterus.) In addition, the urogenital ridges and ovaries
extracted from that animal chimeric embryo are not
embryos, and there are no problems even if they are
transplanted into an animal and matured.
As a strategy to prevent the accidental fertiliza-
tion of human germ cells induced from human iPS
cells, one of the options in this study is to focus only
on oogenesis. By transplanting iPS-derived PGCs
into gonads derived from females, both male and
female-derived iPS cells are advanced to oogenesis,
and all analysis should be by oocyte parthenogenetic
development.
In the case of mice, if the E10.5-derived
urogenital ridge is organ cultured under certain
conditions, it will diﬀerentiate into ovaries but not
testicles.31),32) Therefore, there is no need to be
concerned over the accidental production of human
sperm or the subsequent human fertilized embryos in
the mouse, provided the method given in Fig. 2 is
used, i.e., introducing iPS cell-derived PGC into
genital primordia at this time and diﬀerentiating the
genital primordia that diﬀerentiate into ovaries by
organ culture. Also, when the ovaries that have been
organ cultured are matured in a female mouse, by
selecting transplantation into the renal capsule (not
the location of the ovaries), it is thought that
fertilization of human ooctyes by mouse sperm by
unforeseen mating can be prevented in advance.
As described above, no ethical problems are
assumed to arise in the implementation of this
proposal, but it goes without saying that the
approval of ethics committees at research institu-
tions must be obtained before actual implemen-
tation.
It would be convenient to use a method that
does not employ meiosis, which is diﬃcult to induce
artiﬁcially, for rearranging chromosomes. For exam-
ple, the phenomenon of loss of heterozygosity in
which chromosomes are made partially homozygous
is known. Frequency of this phenomenon is increased
in cells deﬁcient in Bloom’s syndrome gene and
these cells can be used as genetic tools in certain
conditions.53),54) If the few cells in which such a
phenomenon has occurred can be selected, and if
phenotypically changed clones can be speciﬁcally
recognized, it may be possible to exploit this
phenomenon, because the frequency of the phenom-
enon is very low even in the absence of Bloom’s
syndrome gene. However, it is generally diﬃcult to
collect phenotypically changed clones speciﬁcally.
For example, how can one ﬁnd hepatocytes which
recovered their high glycine metabolic activities
mixed in those with low activities when analyzing
NKH? In addition, the resolution that narrows down
the locus is the distance between the recombination
points of the chromosome. However, the frequency of
homologous recombination in mammalian somatic
cells is generally extremely low. Hence, to obtain a
number of recombination points that narrow down
the locus, meiosis is quicker and has a track record of
use in genetic analysis.
Possible application of the procedure. The
experimental technique proposed here can provide
analytical strategies in several research areas where
analysis has previously been problematic.
(1) Single-patient genetics. This method
enables the identiﬁcation of the disease gene loci from
a single carrier of the genetic mutations. It saves costs
to collect samples from many patients. In addition,
this experimental procedure can be applied to cases
where information on population genetics is unavail-
able or whole-genome sequencing cannot be applied,
such as those where only a few patients are available
(e.g., rare diseases or patients having exceptional
mutations in major symptoms) and where each
patient exhibiting the same disease has mutations
on diﬀerent combinations of susceptibility genes
(e.g., IGE).
This procedure can be applied to Mendelian
disorders inherited as dominant and recessive traits
T. MUTO [Vol. 87, 96as well as polygenic diseases. It can also be applicable
to the cases that the mode of disease inheritance
is unclear and whether the diseases are genetic is
unknown.
This is achievable because of the following:
(a) Large sample size. The resolution of gene
mapping by the classical linkage analysis depends
on the sample size available. In contrast to the
conventional human genetic analyses, this method
would enable to extensively narrow down the
candidate gene region by freely increasing the
number of parthenogenetic clones.
(b) Locus homogeneity. In the study of a particular
patient, abnormalities in the parthenogenetic clones
are derived from identical genetic loci. This enables
accurate identiﬁcation of the loci.
In the case of diseases accompanied by so-called
“anticipation,” even persons with a shared pedigree
have mutations of diﬀerent severities on the same
gene, e.g., the diﬀerent number of trinucleotide
repeats and diﬀerent severities of spinocerebellar
degeneration among persons with a certain pedigree.
The diﬀerent severities of the disease within a
pedigree sometimes lead to misjudgment of less
severe patients as healthy cohorts. This makes
correct determination of the responsible loci diﬃcult
using conventional genetic analyses (i.e., both link-
age analysis and whole-genome sequencing strat-
egy). The method proposed in this manuscript is
also beneﬁcial for such cases because each pES
clone from one patient is thought to have identical
mutations.
(c) Deﬁned genetic background. The diversity of the
genetic background of the parthenogenetic clones
from one patient is deﬁned within a certain range.
This leads to a strict correlation between the
responsible mutations and the phenotypes, which
improves the precision of the genetic analyses.
(2) Genetic analysis of cancer cells. In
addition to the usual genetic disease analysis, it is
also possible to identify heterozygous mutations
that cause cancer. Because cancer cells contain
various mutations, there are cases where even reading
the entire cancer cell genome will not reveal which
mutation caused cancer. Also, cancer cells cannot,
of course, be mated, so the cause of cancer cannot
be genetically identiﬁed by mating experiments.
When addressing these kinds of problems, if the
protocols in this proposal are applied to cancer cells,
it will be possible to identify the cause of canceration
of particular cancer cells (if the cause is hetero-
zygous).
The problems of cancer cells containing many
mutations and mating experiments being impossible
are also encountered in mouse cancer cell research.
Hence, useful discoveries can be made even if this
method is applied to mouse cancer research. So long
as the application of this method is conﬁned to mice,
there are no technical or ethical problems.
For example, mouse cancer cells (e.g., liver cancer
cells) are transformed into iPS cells, introduced into
a female mouse blastocyst, and a chimeric mouse
produced. The iPS-derived oocytes from that mouse
are collected, parthenogenetically developed, and pES
cells established. ES cells derived from parthenoge-
netic embryos are diﬀerentiated into the appropriate
cells (e.g., liver cells). Those cells are assessed to check
whether they are tumor cells (transplant experiments
or examination of cell surface markers).
(3) Mammalian random mutagenesis. In
forward genetics in mammals (with particular
progress in research on mice), random mutations
are introduced into the sperm, and the required
mutants are obtained by phenotypic analysis of the
oﬀspring. In the process of searching for recessive
mutations, numerous individuals need to be mated to
make the randomly inserted mutations homozygous.
However, the application of the research method
proposed here can generate a large number of clones
homozygous for the introduced mutation by, for
example, carrying out oogenesis of iPS cells with
randomly introduced mutations, followed by parthe-
nogenetic development and establishing pES cells.
If the pES clones with abnormal phenotypes are
identiﬁed, the causative mutation can be determined
by whole genome sequencing.
This strategy may be particularly eﬀective once
functional oogenesis directly from iPS cells in vitro
becomes possible.
Diﬀerences from conventional human genet-
ics. The experimental protocol proposed here diﬀers
from conventional procedures in the following ways.
(1) Reproduction of abnormalities from iPS
cells. The methods used for experimental human
genetics described above are applicable to genetic
disorders where the symptoms are at least partially
reproducible from iPS cells. The abnormalities to be
reproduced need to be either the cause of the disease
or the eﬀects of the causative defects of the disease.
Because reproduction of the abnormalities using
patient-speciﬁc iPS cells is clinically important to
establish diagnostic protocols and research drugs,
more disease symptoms would be reproduced in the
near future.
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parthenogenetic clones are the same, the proposed
procedure is beneﬁcial for analyses of multifactorial
diseases that are aﬀected by environmental factors.
In the case of slow-onset diseases, potential
patients with no obvious symptoms are sometimes
identiﬁed as healthy. The method proposed here is
suitable for such cases because all the mutant pES
clones from a patient are suspected to be “ill”,o n c e
the experimental protocol is established to reproduce
the symptoms of that patient.
In vitro experimental systems are also useful for
rescue experiments of the iPS cell of the patient in
order to conﬁrm that the identiﬁed mutations are the
ones responsible for the disease. Moreover, the set of
pES clones produced by this method can be used as
a tool to analyze the functional signiﬁcance of the
cloned gene by comparing the phenotypes of the pES
clones and expression levels or functional alteration
of the gene product.
(2) Production of germ cells from iPS cells.
In the proposed experimental protocol for human
genetics, the patient-derived iPS cells have to
undergo meiosis. Although there are several reports
describing the production of germ cells from ES/iPS
cells in vitro, it is still uncertain whether functional
meiosis including correct chromosomal homologous
recombination occurs in vitro. However, ES/iPS cells
can diﬀerentiate into gametes if they are injected
into blastocysts, and the resultant chimeric embryos
develop to term. Therefore, the problem is not the
incapability of producing gametes from iPS cells
in vitro but how to technically and ethically apply
gametogenesis in chimeric embryos to human iPS
cells.
One possible procedure to produce oocytes from
human iPS cells is described in the Method section
and depicted in Fig. 2. Because the development of
PGCs into oocytes requires in vivo conditions, PGCs
derived from human iPS cells have to be transplanted
to nonhumans. The animal species that receives the
human PGCs needs to be chosen. Human teratoma
formation, reconstruction of the human adaptive
immune system,55) and generation of mice with
chimeric human livers56),57) are accomplished after
transplantation of human cells into immune-deﬁcient
mice. Therefore, these immune-deﬁcient mouse lines
may be chosen as recipients of human iPS cell-
derived PGCs.
Correct induction of a functional gamete from
iPS cells is studied intensively because it is a matter of
clinical importance. If functional oocytes are pro-
duced from human iPS cells in vitro in the near future,
this would beneﬁt experimental human genetics.
Meiotic arrest does not occur in the case of
spermatogenesis. Therefore, meiotic arrest and re-
programming to pluripotent stem cells at the
appropriate stages have to be enforced artiﬁcially, if
spermatogenesis is applied to the protocol proposed
in the present report. Whether this is possible
remains to be determined.
(3) Genetic analysis. The experimental
human genetics described here diﬀers from the more
commonly applied human genetics in terms of genetic
analysis, as follows:
(a) Diseases to be studied. If the types of
inheritance of certain genetic diseases are clear,
familial information would have already been ana-
lyzed intensively. Thus, many patients and their
families are expected to be easily accessible. In such
cases, conventional genetic analysis or whole-genome
sequencing strategies are the ﬁrst choice to determine
the disease genes, because these are easier, faster, and
cheaper than the experimental procedure proposed
here. Therefore, only complex diseases or the cases
where only a few patients are accessible should be
analyzed by the experimental human genetics de-
scribed here. In such cases, the number of responsible
or susceptible genes and the types of inheritance
may be unclear. In order to determine the gene loci
responsible for such diseases, statistical procedures
utilized in quantitative trait loci analyses, nonpara-
metric linkage analyses, or association studies are
suitable. So far as the genetic analysis is applied to
the parthenogenetic clones from one patient, pop-
ulation stratiﬁcation is not a concern in contrast to
conventional human genetics.
(b) Mutations to be determined. Heterozygous
dominant mutation loci are determined using pa-
tient-derived iPS cells by the parthenogenetic proce-
dure, if the dominant mutation is one component
of the disease (Fig. 3B(i)). On the other hand, iPS
cells from parents of the patients must be analyzed
to determine the responsible gene loci, if all the
mutations responsible for the diseases are homo-
zygous recessive (Fig. 3B(ii)).
If the susceptibility genes are composed of both
heterozygous dominant and homozygous recessive
mutations, the homozygous recessive loci cannot be
determined using either patient- or parent-derived
parthenogenetic clones in some cases (Fig. 3B(iii)).
However, in order to treat the patient, reversion of
some of the mutations in the susceptibility genes
would be adequate. (If the diseases are not restored
T. MUTO [Vol. 87, 98after reversion of a mutation at all, such mutation
must not have been cloned as that in a susceptibility
gene.) Therefore, it doesn’t matter in that respect,
even if all the mutations of susceptible genes are not
determined.
(c) Genetic bias of chromosomes in the parthenoge-
netic clones. In the parthenogenetic clones derived
from oocytes at the second meiotic metaphase
[hereafter, referred to as p(MII) clones], chromosome
regions proximal to the centromere become homo-
zygous and distal regions remain heterozygous if one
recombination occurs in an arm, as shown in Figs. 1C
and 3A. This kind of chromosomal segregation can be
genetically analyzed by half-tetrad analysis, as well
studied in attached-X chromosomes in Drosophila.58)
(d) Potential recessive mutations in the human
genome. There are several disease-causing recessive
mutations that are heterozygous in the human
genome. In the procedure proposed here, half of the
chromosomes become homozygous in the p(MII)
clones and a quarter in the p(MI) clones (Fig. 3A),
which results in the heterozygous recessive mutations
in the human genome becoming homozygous, which
may produce some disease-causing clones.
If the potential recessive mutations become
homozygous, the pES cells may be aﬀected in the
following ways: (i) diﬀerentiation into cells appro-
priate for analysis is disturbed (e.g.,d i ﬀerentiation
into hepatocytes is disturbed in the analyses of
NKH), (ii) cellular functions to be analyzed are
perturbed (e.g., glycine metabolism is disturbed in
the analysis of NKH), or (iii) an unrelated phenotype
becomes abnormal (e.g., the mutation aﬀects neuro-
genesis and the glycine metabolic activities are
analyzed using pES-derived hepatocytes).
In the case of (i), aﬀected clones that are unable
to diﬀerentiate into cells appropriate for analysis
should be removed from the analyses. Thereafter, the
disease gene loci for the patients are determined
genetically, although analyses of the loci around the
potential mutations become more complicated. In the
case of (ii), mutations responsible for the diseases and
potential recessive mutations are determined simul-
taneously. Thereafter, the potential recessive muta-
tions could be logically discriminated from the
responsible mutations. The potential recessive muta-
tion is found to aﬀect the function of parthenogenetic
cells only when it becomes homozygous, but it is
heterozygous in the patient’s genome. Reversion of
the potential recessive mutation does not restore the
abnormality in patient cells. The eﬀects of (iii) do not
matter at all.
p(MI) clones have lower chromosomal homozygos-
ity than p(MII) clones. p(MI) clones may have lower
risk originated from the potential recessive mutations.
(4) Clonal variability of pES/iPS cells. ES/
iPS cell clones do vary even if they are established
from genetically identical embryos. Eﬀect of the varia-
bility should be overcome during genetic analysis.
(a) Functional variability of diﬀerentiated pES clones.
Even when pES cell lines are established from the
identical parthenogenetic blastocyst, phenotypes
can diﬀer depending on the cell line of the clone.
However, with regard to the phenotypic variation
independent of the genetic variation, it is anticipated
that the impact of the variation will be averaged out
by using a large number of pES clones for genetic
analysis, so that ﬁnally only the loci causing the
disease phenotype will be isolated.
Furthermore, even when the severity of the symp-
toms is diﬀerent in each patient, the causal loci in each
patient can be independently identiﬁed by analyzing
the pES clones produced from each patient separately.
(b) Diﬀerentiation eﬃciency. The eﬃciency with
which pES cells diﬀerentiate into appropriate cells
is not always 100%. In addition, the eﬃciency may
not be same in diﬀerent pES cell clones. Therefore, the
cellular function to be analyzed should be compen-
sated by the eﬃciency of diﬀerentiation into the
appropriate cells. For example, in the case of the
study with NKH, the glycine metabolism of parthe-
nogenetic clones induced to hepatocytes should be
divided by the amount of a hepatocyte marker, such
as albumin, before the genetic analyses. Alternatively,
speciﬁc examination of appropriate cells by FACS
gating or cytological analyses may also be helpful.
The homogeneity of quality and the complete-
ness of diﬀerentiation in ES/iPS cells are of great
importance in regenerative medicine and are thus
expected to be improved in future.
(c) Abnormal karyotype. The chromosome number
of pES/iPS cells is sometimes disrupted during the
establishment or culture of the clones. To remove
clones with chromosomal abnormalities, karyotyping
of the parthenogenetic clones should be performed
before functional analyses. In addition, genome-wide
typing of SNPs identiﬁes the chromosomal loss of
the parthenogenetic clones if all the loci on a certain
chromosome have a single allele.
(d) Mutagenesis. pES/iPS cells may accumulate
mutations on their genomic DNA during cell culture.
However, it is not likely that the mutations may
aﬀect the genetic analyses of the parthenogenetic
clones. One reason is that randomly generated
Experimental human genetics No. 3] 99mutations rarely aﬀect a speciﬁc phenotype to be
analyzed. Even in a random mutagenesis study using
a strong mutagen such as ENU, it is not easy to ﬁnd
appropriate mutants for the analysis of a certain
phenotype. The second reason is that if the multiple
clones of iPS cells are established from a patient and
pES clones from distinct iPS cell clones are subject to
analysis, only a small part of the clones, if any, would
be aﬀected by an identical de novo mutation, which
does not matter to following genetic analysis.
(5) Uniparental genomic imprinting. Par-
thenogenetic embryos of mammalian species cannot
develop to term. However, pES cells can diﬀerentiate
into various types of cell derivatives of three germ
layers.44),45) Therefore, pES cells can be used for the
experimental procedure described in this report.
In the pES cells from parthenogenetic oocytes,
both alleles of the genomic loci are maternally
imprinted. Thus, uniparental imprinting of the pES
clones may aﬀect some cellular functions. It does not
matter if the abnormalities caused by the uniparental
imprinting diﬀer from those of the patient. However,
if uniparental imprinting leads to the same symptoms
as those of the patient or if the mutations responsible
are located near the imprinted loci, it may aﬀect the
genetic analyses, as described in the following cases.
(a) All pES clones become aberrant. If both alleles
of the genetic loci necessary for the phenotype to be
analyzed are suppressed by maternal genomic im-
printing, then all pES clones get aﬀected (Fig. 3C(ii)).
If the functional abnormalities are restored by
artiﬁcial inhibition of the DNA methylation of pES
cells, genetic analyses of parthenogenetic clones may
be possible.
(b) All pES clones become normal. If a disease is
caused by a heterozygous mutation in an imprinted
locus that leads to 50% loss of activity of the gene
(e.g., 50% expression level or 50% activity of the gene
product), the mutation is on an active allele, and
another nonmutated allele is paternally inactive, all
parthenogenetic clones become normal because both
alleles of the genetic loci are maternally active in the
parthenogenetic clones (Fig. 3C(iii)). In such cases,
genetic analyses cannot determine the loci respon-
sible. However, it becomes clear that the diseases
could be cured by parthenogenetic processes. If the
regulation of genomic imprinting restores the abnor-
mality, chemical reagents such as DNA methyltrans-
ferase inhibitor may be candidates for therapeutic
materials. If this is the case, the loci responsible for
the diseases may be found near the paternally
methylated loci.
(c) Some of the clones with responsible mutations
become normal. In case the heterozygous recessive
mutation in a diﬀerentially methylated locus is
responsible for a disease and the normal allele is
paternally inactivated, parthenogenetic clones carry-
ing a heterozygous mutation become phenotypically
normal because both alleles become active after
parthenogenesis (Fig. 3C(iv)). In such cases, only
clones carrying the mutations homozygously get
aﬀected.
Future perspectives. In future, when gene
therapy would be generally accepted as a way to
treat genetic disorders, all patients of the genetic
diseases may try whole-genome sequencing to iden-
tify the causative mutations. These mutations, once
clariﬁed, could be treated by gene therapy. The
techniques proposed could be the only way to treat
patients having genetic diseases with mutations that
cannot be identiﬁed by whole-genome sequencing and
cross-referencing the mutations with public data-
bases.
According to this scenario, most of the genetic
disorders to which these techniques are applied would
have causes beyond the known biological mecha-
nisms. This means that researchers could study only
mutations related to novel mechanisms.
In the studies of genetics, researchers never
know how much scientiﬁc impact the mutants have,
beforehand. Today, most genes are identiﬁed, and
their functions are known or speculated from their
motifs. Therefore, many geneticists may meet the
cases that they clone mutations on common genes.
Such cases will be more common in future. If this is
the case, who would pay cost to generate and study
999 of the common mutants necessary to discover
another one fruitful mutation?
In the case of human genetics, however, patients
with genetic diseases come to the hospitals by
themselves, and pay cost for gene diagnoses. After
the happiness that 999 of the conventional mutations
have been treated, the remaining one fascinating
mutation beyond our knowledge would be identiﬁed
experimentally. Thus, the method of the experimen-
tal human genetics proposed here is also attractive
from the viewpoint of genetics as basic science.
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